Abstract
Interstitial Laser Photocoagulation (ILP) is a method of destroying lesions in the center of solid organs without the need for open surgery. Under image guidance, up to four needles are inserted percutaneously into the tumor through which thin optic fibers are passed into the target lesion. Low power laser light from a semiconductor laser is delivered to gently coagulate the tissue. This ‘dead tissue’ is subsequently resorbed by the body’s normal healing processes. Follow up is achieved with ultrasound imaging. One study is described for assessing ILP for benign fibroadenomas. Fibroadenomas were treated to assess how laser treated breast tissue healed in the long term and we have shown that the necrosed tissue is resorbed without complications over a period of months. Nevertheless, by following treated fibroadenomas (up to 35mm diameter) with ultrasound measurement at 3, 6 and 12 months, in 14 patients, only one lesion was still detectable 12 months after ILP. In appropriate cases, ILP could be an attractive option, as it leaves no scars and should not change the shape or size of the breast. If the present studies are successful, the plan is for a multi-center trial of minimally invasive, thermal ablation of breast cancers.
© 2001 OSA/SPIE
PDF ArticleMore Like This
David C. O. Pickard, Irving J. Bigio, Stephen G. Bown, Gavin M. Briggs, Andrew C. Lee, Paul M. Ripley, and Sunil Lakhani
4432_143 European Conference on Biomedical Optics (ECBO) 2001
Sharon Thomsen and Thomas Ryan
CTuD1 Biomedical Topical Meeting (BIOMED) 1999
Brian C. Wilson and Douglas R. Wyman
TuL.1 OSA Annual Meeting (FIO) 1993